CL2013000732A1 - Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion. - Google Patents

Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.

Info

Publication number
CL2013000732A1
CL2013000732A1 CL2013000732A CL2013000732A CL2013000732A1 CL 2013000732 A1 CL2013000732 A1 CL 2013000732A1 CL 2013000732 A CL2013000732 A CL 2013000732A CL 2013000732 A CL2013000732 A CL 2013000732A CL 2013000732 A1 CL2013000732 A1 CL 2013000732A1
Authority
CL
Chile
Prior art keywords
constipation
agonists
pain
prevention
activity
Prior art date
Application number
CL2013000732A
Other languages
English (en)
Inventor
Donald J Kyle
Laykea Tafesse
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of CL2013000732A1 publication Critical patent/CL2013000732A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de análogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composición que los comprende; su método de preparación; y su uso para el tratamiento o prevención del dolor o constipación.
CL2013000732A 2010-09-21 2013-03-18 Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion. CL2013000732A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38491210P 2010-09-21 2010-09-21
US201161503674P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
CL2013000732A1 true CL2013000732A1 (es) 2013-07-26

Family

ID=44903285

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000732A CL2013000732A1 (es) 2010-09-21 2013-03-18 Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.

Country Status (34)

Country Link
US (1) US9221831B2 (es)
EP (1) EP2619212B1 (es)
JP (2) JP5977240B2 (es)
KR (2) KR101630912B1 (es)
CN (2) CN105399751A (es)
AR (1) AR083062A1 (es)
AU (1) AU2011306644B2 (es)
CA (1) CA2810356C (es)
CL (1) CL2013000732A1 (es)
CO (1) CO6690803A2 (es)
CR (1) CR20130129A (es)
CY (1) CY1117227T1 (es)
DK (1) DK2619212T3 (es)
DO (1) DOP2013000060A (es)
EA (1) EA201390422A1 (es)
EC (1) ECSP13012543A (es)
ES (1) ES2566828T3 (es)
HR (1) HRP20160281T1 (es)
HU (1) HUE027195T2 (es)
ME (1) ME02367B (es)
MX (1) MX2013003354A (es)
NI (1) NI201300032A (es)
NZ (1) NZ609200A (es)
PE (1) PE20140020A1 (es)
PH (1) PH12013500530A1 (es)
PL (1) PL2619212T3 (es)
RS (1) RS54579B1 (es)
SG (1) SG188300A1 (es)
SI (1) SI2619212T1 (es)
SM (1) SMT201600088B (es)
TW (2) TW201242968A (es)
UY (1) UY33618A (es)
WO (1) WO2012038813A1 (es)
ZA (1) ZA201301217B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
RU2589692C2 (ru) 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
AU2012253653A1 (en) 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
EP2788358B1 (en) 2011-12-08 2018-08-29 Purdue Pharma LP Quaternized buprenorphine analogs
US9315514B2 (en) * 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
EP2931729B1 (en) 2012-12-07 2019-02-06 Purdue Pharma LP Buprenorphine analogs as opiod receptor modulators
CA2900023A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) * 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3087078B1 (en) * 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9656962B2 (en) 2013-12-26 2017-05-23 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
WO2015100092A2 (en) * 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta analogs of orvinols
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3148535A4 (en) 2014-05-27 2017-11-29 Purdue Pharma LP Spirocyclic morphinans and use thereof
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
SG11201803268TA (en) * 2015-10-26 2018-05-30 Orphomed Inc Ethylene glycol ether of buprenorphine
CA3017048C (en) * 2016-03-22 2023-11-07 Helsinn Healthcare Sa Benzenesulfonyl-asymmetric ureas and medical uses thereof
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
US11390628B2 (en) 2017-05-19 2022-07-19 River Stone Biotech Llc Preparation of buprenorphine
JP2021104932A (ja) * 2018-03-30 2021-07-26 日本ケミファ株式会社 モルヒナン誘導体の製造方法
EP4577204A1 (en) * 2022-08-23 2025-07-02 Virginia Commonwealth University Multiple targeting opioid receptor ligands as novel analgesics with minimum abuse liability
WO2024211482A2 (en) * 2023-04-04 2024-10-10 Board Of Regents, The University Of Texas System METHODS OF SYNTHESIZING 14-β-AMINOMORPHANS AND SALTS THEREOF

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136764A (en) * 1965-08-13 1968-12-18 Reckitt & Sons Ltd Derivatives of thebaine and oripavine
US6258825B1 (en) 1997-05-30 2001-07-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
HUP0101275A3 (en) 1998-03-26 2002-12-28 Japan Tobacco Inc Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
NZ528241A (en) 2001-03-02 2004-08-27 Euro Celtique S N-but-3-enyl norbuprenorphine and methods of use
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
ES2286461T3 (es) 2002-09-25 2007-12-01 Euro-Celtique S.A. Hidroformas n-substituidss y uso de las mismas.
AU2003285934A1 (en) 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US6958398B1 (en) 2002-12-30 2005-10-25 Euro-Celtique S.A. Methods for making thebaine or its acid salts
PT2079485E (pt) 2006-11-01 2012-08-13 Purdue Pharma Lp Compostos fenilpropionamida e a sua utilização
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
EP2620437A1 (en) 2007-11-30 2013-07-31 Purdue Pharma LP Benzomorphan compounds
UA104004C2 (uk) * 2008-07-30 2013-12-25 Пердью Фарма Л.П. Аналоги бупренорфіну
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
EP2788358B1 (en) 2011-12-08 2018-08-29 Purdue Pharma LP Quaternized buprenorphine analogs
TW201408645A (zh) 2012-05-11 2014-03-01 Purdue Pharma Lp 苯並嗎凡類似物及其用途
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
EP2931729B1 (en) 2012-12-07 2019-02-06 Purdue Pharma LP Buprenorphine analogs as opiod receptor modulators
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
EP2931725B1 (en) 2012-12-14 2017-02-15 Purdue Pharma LP Nitrogen containing morphinan derivatives and the use thereof
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
WO2014102587A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. 7,8-cyclicmorphinan analogs
CA2896202A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
CA2900023A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
WO2015100092A2 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta analogs of orvinols
US9340542B2 (en) 2013-12-26 2016-05-17 Purdue Pharma L.P. Propellane-based compounds and the use thereof
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands

Also Published As

Publication number Publication date
PH12013500530A1 (en) 2017-08-09
AR083062A1 (es) 2013-01-30
TW201242968A (en) 2012-11-01
EA201390422A1 (ru) 2014-01-30
UY33618A (es) 2012-03-30
AU2011306644B2 (en) 2015-07-02
JP2013543488A (ja) 2013-12-05
NZ609200A (en) 2015-01-30
PE20140020A1 (es) 2014-01-31
KR20150027315A (ko) 2015-03-11
KR20130097210A (ko) 2013-09-02
PL2619212T3 (pl) 2016-09-30
ME02367B (me) 2016-06-20
SMT201600088B (it) 2016-04-29
EP2619212B1 (en) 2016-01-06
HUE027195T2 (en) 2016-10-28
TW201422621A (zh) 2014-06-16
HRP20160281T1 (hr) 2016-04-08
CA2810356A1 (en) 2012-03-29
MX2013003354A (es) 2013-06-24
CN105399751A (zh) 2016-03-16
US9221831B2 (en) 2015-12-29
CA2810356C (en) 2016-06-14
US20140057931A1 (en) 2014-02-27
AU2011306644A1 (en) 2013-04-11
DOP2013000060A (es) 2013-04-30
CO6690803A2 (es) 2013-06-17
CR20130129A (es) 2013-08-29
CY1117227T1 (el) 2017-04-05
NI201300032A (es) 2014-01-13
SG188300A1 (en) 2013-04-30
SI2619212T1 (sl) 2016-04-29
WO2012038813A1 (en) 2012-03-29
DK2619212T3 (en) 2016-03-21
HK1187045A1 (en) 2014-03-28
ECSP13012543A (es) 2013-06-28
CN103154000A (zh) 2013-06-12
EP2619212A1 (en) 2013-07-31
ES2566828T3 (es) 2016-04-15
JP5977240B2 (ja) 2016-08-24
ZA201301217B (en) 2013-09-25
RS54579B1 (sr) 2016-06-30
JP2016102115A (ja) 2016-06-02
KR101630912B1 (ko) 2016-06-15

Similar Documents

Publication Publication Date Title
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
CO7400870A2 (es) Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
ECSP13012519A (es) Compuestos sustituidos de benzamida
CL2017002017A1 (es) Compuestos con actividad antagonista de los receptoresmuscarínicos y actividad agonista del receptor beta2 adrenérgico
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
DOP2014000098A (es) 2-tiopirimidinonas
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
BR112015012720A2 (pt) derivados de feniletilpiridina como inibidores de pde4
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
MX2016008130A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
MX2017016939A (es) Novedosas antagonistas 5-ht2.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
CL2012003253A1 (es) Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico.